Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine
| Autor: | Gisolf, E. H., Dreezen, C., Danner, S. A., Weel, J. L.F., Weverling, G. J., Reiss, P., Duurvoort, M., Krijger, E., Brouwer, E., Visser, G. R., Klotz, A., Benschop, C., Wulfert, F., Wolf, F. De, Jurriaans, S., Portegies, P., Colebunders, R., Pelgrom, J., Wijnants, H., DE Roo, A., Keersmaekers, K., Vandenbruane, M., Branden, D. Van Den, James, T., Wanzeele, F. Van, Gucht, B. Van Der, Van Der Ende, M. E., Nouwen, J., Deenenkamp, R., Van Der Meyden, D., Koopmans, P. P., Brinkman, K., Ver Hofstede, H., Zomer, B., Blok, W. L., Ruissen, C., Sprenger, H., Law, G., Meulen, P. Vander, Veen, C. Ten, Juttmann, J. R., Heul, C. Vander, Santegoets, R., Ven, B. Vander, Kate, R. W.Ten, Schoemaker, M., Kauffmann, R. H., Henrichs, J. M., Maat, A., Prins, E., Napel, C. H.H.Ten, Pogany, K., Duyts, T., Simons, P., Lacor, P., Waele, A. De, Wijngaarden, E. Van, Lejeune, M., Nieuwkerk, P., Sprangers, M., Roos, M., Scholte, R., Dijkman, J., Japour, A. J., Borst, M. J., Leeuwen, E. Van |
|---|---|
| Přispěvatelé: | Internal Medicine, Medical Microbiology & Infectious Diseases, Internal medicine, Prometheus Study Group, Faculteit der Geneeskunde |
| Jazyk: | angličtina |
| Rok vydání: | 2000 |
| Předmět: |
Microbiology (medical)
medicine.medical_specialty HBsAg viruses Viral diseases Gastroenterology digestive system SDG 3 - Good Health and Well-being Internal medicine medicine Risk factor Saquinavir Ritonavir biology Adverse effects business.industry Stavudine biochemical phenomena metabolism and nutrition Confidence interval Infectious Diseases Liver Alanine transaminase Relative risk Immunology embryonic structures HIV-1 biology.protein sense organs Drug therapy business medicine.drug |
| Zdroj: | Clinical Infectious Diseases, 31(5), 1234-1239. Oxford University Press Clinical Infectious Diseases, 31(5), 1234-1239 Gisolf, E H, Dreezen, C, Danner, S A, Weel, J L F, Weverling, G J, Reiss, P, Weverling, G J, Duurvoort, M, Krijger, E, Brouwer, E, Visser, G R, Klotz, A, Benschop, C, Wulfert, F, Danner, S A, Wolf, F D, Jurriaans, S, Portegies, P, Colebunders, R, Pelgrom, J, Wijnants, H, DE Roo, A, Keersmaekers, K, Vandenbruane, M, Branden, D V D, James, T, Wanzeele, F V, Gucht, B V D, Van Der Ende, M E, Nouwen, J, Deenenkamp, R, Van Der Meyden, D, Koopmans, P P, Brinkman, K, Ver Hofstede, H, Zomer, B, Blok, W L, Ruissen, C, Sprenger, H, Law, G, Meulen, P V, Veen, C T, Juttmann, J R, Heul, C V, Santegoets, R, Ven, B V, Kate, R W T, Schoemaker, M, Kauffmann, R H, Henrichs, J M, Maat, A, Prins, E, Napel, C H H T, Pogany, K, Duyts, T, Simons, P, Lacor, P, Waele, A D, Wijngaarden, E V, Lejeune, M, Wijngaarden, E V, Lejeune, M, Nieuwkerk, P, Sprangers, M, Roos, M, Scholte, R, Dijkman, J, Japour, A J, Borst, M J & Leeuwen, E V 2000, ' Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine ', Clinical Infectious Diseases, vol. 31, no. 5, pp. 1234-1239 . https://doi.org/10.1086/317449 Clinical infectious diseases, 31, 1234-1239. Oxford University Press |
| ISSN: | 1058-4838 |
| DOI: | 10.1086/317449 |
| Popis: | Liver enzyme elevation (LEE) is commonly observed after combination antiretroviral therapy (ARVT) for HIV infection is begun. Potential risk factors for LEE after treatment with ritonavir and saquinavir with or without stavudine were investigated in 208 HIV-infected patients, by use of the Cox proportional hazard model. Eighteen patients (9%) developed LEE during the 48-week follow-up. Multivariate analysis, adjusted for baseline levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), showed that hepatitis B surface antigen (HBsAg) positivity (relative risk [RR], 8.8; 95% confidence interval [CI], 3.3-23.1) and the use of stavudine (RR, 4.9; 95% CI, 1.5-16.0) were the only significant risk factors for developing LEE. After LEE occurred, ALT and AST concentrations decreased by >50% in 13 of 14 patients who continued ARVT during LEE. In this study, it appeared safe to continue ARVT during LEE; however, more data from larger studies are required to confirm this finding. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|